Seize the Opportunity: Invest Today.
Seize the Opportunity: Invest Today.
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from The Market Observer.
Imagine investing in a medical breakthrough that could transform millions of lives. This company is revolutionizing AL Amyloidosis and autoimmune disease treatment with cutting-edge technology. Why invest now? Read on and <Click Here to Learn More> Large Market Potential: AL Amyloidosis affects 30,000 people in North America. In a $3 billion market with health insurance reimbursements of $350K-$450K per treatment. Advanced Technology: The proprietary CAR-T system targets and deactivates disease-causing cells deep within the body, offering hope where traditional treatments have failed. Attractive Valuation: In a market dominated by antibody treatments, this company with its advanced technology stands out with a significantly lower market cap than its peers, highlighting substantial potential upside. Ready to Learn More? <Click here to see the details of this exciting opportunity > Regards, The Market Observer |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of IMMIX Biopharma (NASDAQ: IMMX). The compensation consists of up to $2,800 and was received/will be received from Investing Media Solutions. This compensation should not be considered as an endorsement of the securities of adviser IMMIX Biopharma (NASDAQ: IMMX) and we are not responsible for any errors or omissions in any information provided about the securities of IMMIX Biopharma (NASDAQ: IMMX) The Market Observer. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 7/3/24.
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Unsubscribeinvisiblelink
|
|
Tidak ada komentar:
Posting Komentar